Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia - Wikidata - awgldk - TriplyDB

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

http://www.wikidata.org/entity/Q28295044

about

Analysis of arterial intimal hyperplasia: review and hypothesis Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit The failure of torcetrapib: what have we learned?Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies High shear stress induces atherosclerotic vulnerable plaque formation through angiogenesis Unmet Needs in LDL-C Lowering: When Statins Won't Do!High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties CETP Inhibition: Past Failures and Future Hopes Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics Familial hypercholesterolemia: present and future management Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients JTT-705: is there still future for a CETP inhibitor after torcetrapib?Use of targeted exome sequencing in genetic diagnosis of Chinese familial hypercholesterolemia The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.Carotid intima-media thickness studies: study design and data analysis.Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Tobacco Smoke Exposure Reduces Paraoxonase Activity in a Murine Model.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta.Gene-environment interactions of CETP gene variation in a high cardiovascular risk Mediterranean population Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Low high-density lipoprotein cholesterol: current status and future strategies for management.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Commentary on the clinical management of metabolic syndrome: why a healthy lifestyle is important.Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.Emerging drugs for hyperlipidemia.Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.Familial hypercholesterolemia: current treatment and advances in management.Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.

P2860

Q21245222-24CE6A32-DFE2-4D16-A7B1-2B44AF59BE4B Q24648125-81DED8D8-28B8-4CD5-986F-EFAADA0E7402 Q24650533-C5D5CA7C-1D70-4F91-BA37-3272CB5D6E1D Q24652526-1BA2155E-8EFB-4177-9792-3E79329ADE0E Q26738588-CEDC58B9-591F-40C6-BD48-F5570BF05DFA Q26740033-C095C7A2-1177-45BF-9B1B-798EEC30BE7B Q26741705-89841F3F-A10B-4B3D-9205-E6E9A8086C4E Q26750603-CE274974-AA5A-4BD4-8493-AC4DB17CF625 Q26753158-1FC4AA26-F6BD-4C5A-9CA8-32D11C923830 Q26774903-9E3E6A7C-9577-4CAC-93FF-B968086EF47E Q26828489-7C630CEB-A7F2-4035-8E9D-750578519CD4 Q27672820-47A5AD44-BAAF-498E-BFE3-63F43D7F9BBA Q28244205-563EAE6E-78B0-4D8C-8E69-65DBE6DE5E2A Q28294797-BE81AE99-55F0-49C9-8F7C-0A1976A36767 Q28537747-04254DFB-00B7-455A-BAA8-7B44560A5962 Q30380628-64559A35-604D-40A1-9875-44CFC7B6B468 Q30401532-516F05DD-AD19-4695-8F04-815FB1285337 Q30712446-4EFD01FC-AB3D-4C52-A2E1-758AB966719B Q33569541-45ED673D-0407-4587-881B-B3814665D106 Q33590777-24AE46B8-830E-43F2-BA58-7F9087FCE596 Q33612543-7F1AFE2E-5A37-4C55-A0A5-544EDBC46B5A Q33634188-53D3CAF9-0814-43C4-ADA1-2AA90681C76E Q33639433-913AB0E7-C864-44FF-940E-B96C6C75CC58 Q33650636-6F63256A-07E9-4805-B552-4CBF17088049 Q33993233-601ABC45-B00E-4635-B31D-9A7CFDC8172D Q34009628-5513B502-89EE-4E65-8566-E6FBF93A0CF3 Q34053189-DB6E6B89-94E6-4792-BA6E-FA2363E662A4 Q34169725-E7B75677-4976-4649-9B02-5BCFB78C715E Q34181607-1BF42CD1-29A7-4A4C-8698-986E350BDCE0 Q34243501-133E4F3F-4DF4-4BC2-B80C-E7EA1C283C82 Q34253290-239DA0A1-67C8-4180-B473-09003E18F973 Q34334846-64030806-47C3-407D-9127-762B9CCF1CD5 Q34441411-8435AA44-7395-4F6F-B04A-F4BB3090357A Q34476797-B6C34F6B-4E35-4F5C-B2ED-D53B8F07D085 Q34571030-4F3B24A0-8025-46D4-A32C-CB90B449E3E6 Q34619115-DAEFFDD3-308A-4D04-9E07-FC05CFBB5E8A Q34628218-B4FBB29A-2137-4D3B-8AA9-CCE792CC7912 Q34635305-406DA767-0A04-4A2D-A243-F80F71A7E267 Q34769059-1DD7DFD5-4CDA-4397-9C6C-40A03D5BBA77 Q34931247-73AA8A9B-3757-4E0C-B6A1-F29E9743EE47

P2860

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

http://www.wikidata.org/entity/Q28295044

description

2007 nî lūn-bûn

@nan

2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@ast

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@en

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@nl

type

label

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@ast

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@en

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@nl

prefLabel

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@ast

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@en

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@nl

P1433

Q28295044-BD6F34A2-B55A-4FE5-8D5F-437A2E0DFBD3

P1476

Q28295044-C97CD8DA-82BC-4E1E-8FC6-6EB0EBA5F82E

P2093

Q28295044-06E690D3-9E72-4313-9FFA-86AB08D3C5B9

Q28295044-1A58EC9D-26A8-4853-B2DD-2A006DE46D54

Q28295044-30C98795-F6C4-4991-8501-B7F9CD410421

Q28295044-5EE99FC8-705C-45FD-B52A-3BC3CAA979E7

Q28295044-9147D9E1-EF4C-404D-81B1-A8926CB8D401

Q28295044-A7018519-5EA8-4AE4-8ACB-292272D054FE

Q28295044-A9E44D1C-2E36-4374-BA9C-51259D2E80FF

Q28295044-B7547A5F-2EE6-4475-BE51-0C65C0372457

Q28295044-BB0AE9DB-9C64-4EED-8A75-91975C49048E

Q28295044-BEE9DA75-EA78-490C-9473-4ED5666CD537

P304

Q28295044-554B0874-199C-4CF9-8235-07368ADB32E4

P31

Q28295044-CEC1937E-9A5C-4052-BA5F-872695A51A7C

P3181

Q28295044-E7C43B77-15F0-446E-B260-688FE19A3802

P356

Q28295044-80DCFD05-6541-4DC7-96C3-40670DB5B9BA

P407

Q28295044-2B22BD5A-94E5-428A-8B41-A56CB991B72E

P433

Q28295044-B74637C1-79D2-452C-A10C-AEB997C6A4E5

P478

Q28295044-4D58FA16-33A8-447C-855F-0D6167C1DF96

P50

Q28295044-0670CB9F-D7FA-440B-BB43-39C2C781CA02

P577

Q28295044-B17E2633-36E8-4DA2-893C-7DBE07944ADD

P698

Q28295044-6B70E26A-8126-4E91-9FF7-8B0596A97DC6

P921

Q28295044-3725BF8E-02F8-4C39-9B2A-11384CB3234D

Q28295044-82433549-3728-4818-9C46-B4AEB76A17FA

P3181

P356

P1433

The New England Journal of Medicine

P1476

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

@en

P2093

Charles L Shear

http://www.w3.org/2001/XMLSchema#string

Greg W Evans

http://www.w3.org/2001/XMLSchema#string

James H Revkin

http://www.w3.org/2001/XMLSchema#string

Jan A Kuivenhoven

http://www.w3.org/2001/XMLSchema#string

John J P Kastelein

http://www.w3.org/2001/XMLSchema#string

Leslie Burgess

http://www.w3.org/2001/XMLSchema#string

Michiel L Bots

http://www.w3.org/2001/XMLSchema#string

Philip J Barter

http://www.w3.org/2001/XMLSchema#string

Sander I van Leuven

http://www.w3.org/2001/XMLSchema#string

Ward A Riley

http://www.w3.org/2001/XMLSchema#string

P304

1620-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1298740

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA071359

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P50

Diederick E Grobbee

P577

2007-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17387131

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

hypercholesterolemia